Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of XVR011 in healthy adults
NL-OMON49939Phase 1Completed
- Sponsor
- ExeVir Bio
- Start
- Aug 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of VHH72-Fc in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by ExeVir Bio. Primary endpoint: Safety and tolerability. Started Aug 2021; status: completed.
02
Drugs
VHH72-Fc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49939.